Home / News
The human microbiome and its immense impact on the health conditions of the human body has become a vital topic in international biomedical research – as shown lately in a interesting article in the British daily The Guardian.
In 2018, two big European meetings co-organized by INFRAFRONTIER will cover the role of animal research for studying the microbiome:
This is the first stakeholder meeting of INFRAFRONTIER, the European Research Infrastructure for phenotyping and archiving of model mammalian genomes. The meeting will be jointly organized with the International Mouse Phenotyping Consortium (IMPC, www.mousephenotype.org) to which INFRAFRONTIER is contributing. Focus of this meeting is on ‘Advancing Personalised Medicine with Animal Models’. The meeting is open to a wide range of INFRAFRONTIER stakeholders including Personalised Medicine initiatives, Rare Disease networks, funders, regulators and the INFRAFRONTIER user community to discuss advances in CRISPR/Cas9 technology to model human conditions.
INFRAFRONTIER will be present at the ISTT 13th Transgenic Technology Meeting, March 20-23, Prague, Czech Republic.
You are welcome to visit us at stand 25 and learn more about INFRAFRONTIER!
On July 21-22, INFRAFRONTIER IPAD-MD project was kicked-off, in a two-day meeting in Munich, Germany.
On 19 November 2014 the Council of the INFRAFRONTIER GmbH met in Munich for its third regular meeting. The Council discussed and approved the work programme, budget and the overall scientific strategy for the INFRAFRONTIER GmbH in 2015.
On 07 May 2014 the Council of the INFRAFRONTIER GmbH met in Munich. This was the first meeting of the Council after the accession of France, Czech Republic, Finland and Greece to the INFRAFRONTIER GmbH on 05 December 2013.